Myeloproliferative neoplasm screening: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Mmir (talk | contribs)
CMEAdmin, CMEUser, Bureaucrats, bureaucrats, nocaptcha, smwadministrator, Administrators, Widget editors
14,850 edits
Mahshid
Shyam Patel (talk | contribs)
nocaptcha
3,105 edits
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myeloproliferative disease}}
{{Myeloproliferative disease}}
{{CMG}} {{AE}} {{MJK}}  
{{CMG}} {{AE}} {{MJK}} {{shyam}}
 
==Overview==
==Overview==
Screening for myeloproliferative neoplasm by quantitative cell-based ''[[JAK2|JAK2V617F]]'' mutation assays may be helpful among patients with [[erythrocytosis]], [[thrombocytosis]], splanchnic vein thrombosis, and unexplained ''[[BCR|BCR-ABL]]'' negative [[granulocytosis]].<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416  }} </ref>
There are currently no guidelines for screening for myeloproliferative neoplasm.
 
==Screening==
==Screening==
Screening for myeloproliferative neoplasm by quantitative cell-based ''[[JAK2|JAK2V617F]]'' mutation assays may be helpful among patients with the following:<ref name="pmid21723416">{{cite journal| author=Tefferi A, Noel P, Hanson CA| title=Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. | journal=J Mol Diagn | year= 2011 | volume= 13 | issue= 5 | pages= 461-6 | pmid=21723416 | doi=10.1016/j.jmoldx.2011.05.007 | pmc=PMC3157620 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21723416  }} </ref>
There are currently no guidelines for screening for myeloproliferative neoplasm. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.
*[[Erythrocytosis]]
 
*[[Thrombocytosis]]
*Splanchnic vein thrombosis
*Unexplained ''[[BCR|BCR-ABL]]'' negative [[granulocytosis]]


==References==
==References==

Revision as of 21:54, 20 June 2018

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm screening

on Myeloproliferative neoplasm screening

Myeloproliferative neoplasm screening in the news

Blogs on Myeloproliferative neoplasm screening

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

There are currently no guidelines for screening for myeloproliferative neoplasm.

Screening

There are currently no guidelines for screening for myeloproliferative neoplasm. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.


References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Myeloproliferative_neoplasm_screening&oldid=1478361"